monobasic potassium phosphate + dibasic potassium phosphate

Monobasic potassium phosphate + dibasic potassium phosphate is an intravenous phosphate replacement drug composed of two inorganic potassium phosphate salts in a concentrated sterile solution for dilution before infusion. It is used to treat hypophosphatemia, particularly when oral or enteral phosphate replacement is not feasible, insufficient, or contraindicated, including in adults and in pediatric patients of appropriate body weight. Pharmacologically, the product acts as a **systemic phosphate and potassium electrolyte replacement**, supplying bioavailable phosphate to restore depleted serum phosphorus stores and contributing potassium as a counterion; it does not act through a receptor-mediated or biologic pathway. The product has been developed and commercialized as generic or branded hospital injectable formulations by companies including CMP Development, Fresenius Kabi, Amneal, Hospira, and Pfizer, and is administered by the **intravenous** route after dilution under clinical monitoring because of risks related to electrolyte shifts, hyperkalemia, hypocalcemia, and renal impairment.

Brand names

Potassium Phosphates InjectionDBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection

Other names

monobasic potassium phosphate + dibasic potassium phosphatepotassium phosphates injectionpotassium phosphate injectionpotassium phosphatespotassium dihydrogen phosphate + dipotassium hydrogen phosphateKH2PO4 + K2HPO4